TS-075261 — Problem Hemolysis, the process by which the red blood cell membrane ruptures, releasing hemoglobin (Hb), is typically managed in mammalian organisms by intrinsic proteins such as hemopexin (Hpx) and haptoglobin (Hp). However, their concentrations in plasma are very limited, so, in conditions with s…

TS-075238 — Problem Low titer group O whole blood (LTOWB) is the gold standard used by the US military to treat blood loss. However, there is a limited supply with ex vivo storage and shelf-life limitations. There is no whole blood substitute on the market when LTOWB is not available. Solution Dr. Andre Palmer and team have developed several whole blood substitute formulations to mimic the 3 main functions of whole blood: 1) oxygen transport (provided by hemoglobin-based oxygen carrier [HBOC]); 2) clotting (provided by tranexamic acid); and 3) volume replacement (provided by a plasma substitute). The HBOC consists of T-state polymerized human hemoglobin (PolyhHb). The clotting agent consists of tranexamic acid (TXA). The volume replacement solution consists of polymerized human serum albumin (PolyHSA). Additional additives include high molecular weight polyethylene glycol as a drag reducing agent, and dexamethasone as an anti-inflammatory agent. Applications Prehospital and austere environments Used by EMS and military for early resuscitation before hospital arrival Hospital trauma protocols Used for first-line transfusion in exsanguinating patients Advantages Mimics the three major functions of whole blood without the risk of blood type incompatibility and disease transmission Extended shelf life versus whole blood Scalable production Seeking opportunities for out-licensing and collaboration

TS-075231 — Problem Despite recent progress in cancer therapy, acquired resistance to existing cancer drugs reduces therapeutic efficacy. There is a strong need for a therapy with a novel mode of action to overcome drug resistance, and to improve therapeutic efficacy whether used alone or in combination therap…

TS-062540 — General methods for purifying proteins that can be used in various applications such as targeted drug delivery, bioimaging, and hemolysis treatment.

TS-061547 — A venous access port device that leverages near-field communication (NFC) to automate needle placement as well as a disposable needle cartridge to increase the ease of and help maintain aseptic access to the port.

TS-057739 — CRISPR/Cas 9 mediated targeting of MIR155HG in primary human T cells creates genomic deletions that disrupt transcription of mature microRNA-155 (miR-155, a miR associated with inflammation). Applying this treatment to donor T cells prior to allogenic hematopoietic stem cell transplantation (allo-HSCT) when treating hematological malignancies and other primary bone marrow disorders can prevent the development of aGVHD in patients.

TS-053103 — Uncontrolled hemolysis (i.e., destruction of red blood cells) is characterized by the increase of circulating toxic cell-free hemoglobin, heme and iron in the bloodstream. In vivo, the body’s natural supply of plasma scavenger proteins acts to neutralize these toxic species. However, these scavenger proteins such as haptoglobin, hemopexin and transferrin, which detoxify hemoglobin, heme and iron, respectively, are depleted in various clinical conditions such as hemorrhagic shock, burns, surgery, organ transplantation, sepsis and trauma. Dr. Andre Palmer’s lab at The Ohio State University has developed a novel therapeutic protein mixture, which can be used to treat plasma protein imbalances or depletion caused by the adverse events described above. The properties of this protein mixture are beneficial as they lend themselves to an inexpensive manufacturing process and potential improvements in clinical outcomes.

TS-049827 — circPCMTD1 is a novel target in p53 mutated leukemias.

TS-014895 — Identified gene target for treatment of human acute leukemia, brain tumors and melanoma